After taking a shot at becoming a neuroscience biotech, buzzy Bay Area AI outfit Verge Genomics is dropping its only clinical ...

A new mental health-driven biotech has arrived in Syremis Therapeutics. | Founded by a team of neuropsychiatric-focused Teva ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

The company rolled out Wi-Fi and 5G connectivity across its installed base of Maestro surgical robots, which it describes as ...

Following years in development, the Finnish medtech GlucoModicum has unveiled its needle-free glucose monitoring patch, ...

As support from the U.S. government has evaporated, Moderna is leaning on an old ally to carry plans for its prospective mRNA ...

Early Thursday, Takeda revealed top-line data for two pivotal phase 3 trials of its next-gen, highly selective oral tyrosine ...

After reportedly flirting with going public for years, the artificial intelligence-powered drug developer Insilico Medicine has laid out plans to raise about $292 million through a listin | The IPO ...

Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.

With a late-stage miss reported for its prospective social anxiety disorder (SAD) treatment fasedienol, Vistagen’s chances at ...